2024-01-30 13:43:22 ET
Summary
- Elevance Health reported Q4 earnings that beat expectations for both EPS and revenue.
- The company exceeded its 2023 guidance but disappointed with its 2024 guidance, predicting flat to low single-digit revenue growth.
- Potential risks to Elevance's business model include legislation targeting pharmacy benefit managers (PBMs) and tightening standards on Medicare star ratings.
- DCF analysis, which generated a price target of $559, indicates a substantial margin of safety against business risk and industry headwinds, making Elevance a solid buy.
Elevance Health, Inc. ( ELV ) reported earnings on January 24th with a favorable reception....
Read the full article on Seeking Alpha
For further details see:
Elevance Health Q4: Undervalued Despite Risks To Core Business